Gross Research recently announced the results of an analysis of the global MASH (metabolic steatohepatitis) treatment ...

Roche Holding AG's acquisition of 89bio, Inc. to expand cardiometabolic offerings and drive growth beyond GLP-1. Click for ...

Roche Holding AG acquires 89bio Inc. for $3.5B, adding promising MASH and hypertriglyceridemia treatments. Click for more on ...

Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for ...

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. | ...

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated ...

The stage is set for the Federal Reserve’s meeting next week. The markets surged higher after the August reading on producer ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $502.67, with a ...

Detailed price information for Coreweave Inc Cl A (CRWV-Q) from The Globe and Mail including charting and trades.

Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) ...